pioglitazone has been researched along with pyruvaldehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adeshara, KA; Agrawal, SB; Gaikwad, SM; Tupe, RS | 1 |
| Donahue, RR; Laird, DE; Oliveira, MCG; Santos, DFS; Taylor, BK | 1 |
2 other study(ies) available for pioglitazone and pyruvaldehyde
| Article | Year |
|---|---|
Pioglitazone inhibits advanced glycation induced protein modifications and down-regulates expression of RAGE and NF-κB in renal cells.
Topics: Animals; Biomarkers; Cattle; Dose-Response Relationship, Drug; Down-Regulation; Free Radical Scavengers; Glycosylation; HEK293 Cells; Humans; Interleukin-6; Intracellular Space; Kidney; Lipid Peroxidation; NF-kappa B; Oxidative Stress; Pioglitazone; Pyruvaldehyde; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Serum Albumin, Bovine; Tumor Necrosis Factor-alpha | 2018 |
The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; Morphine; Neuralgia; Nociceptive Pain; Pain, Postoperative; Peripheral Nerve Injuries; Pioglitazone; PPAR gamma; Pyruvaldehyde; Sex Characteristics | 2022 |